Espoo, 18 November 2021 – Nordic BioTech Group Ltd, marketed as NordShield® ("NordShield®") is pleased to announce its disinfectant series "Brilliant" to be introduced to the Asian market through Mantap Perintis Sdn Bhd. ("Mantap")
NordShield® has entered a partnership with Kuala Lumpur based Mantap to initiate the market entry of NordShield® Brilliant disinfectants to the Asian market through a white label collaboration. The products, branded by Mantap under SafeShield, will, as a first step, be sold in Malaysia from Q1 2022.
The NordShield® Brilliant series has three products on the market:
Brilliant Surfaces for hard surfaces,
Brilliant Hands for hand disinfection and
Brilliant Fresh for shoes, performance gear and feet for odor control
"At Mantap, we take pride in offering the newest and highest quality technology to our customers and are thus thrilled to collaborate with pioneering NordShield®. We are excited to bring this unique technology to the quality and performance conscious Asian market, and we look forward to a long-term collaboration with NordShield®."
- Wong Wei Khen, CEO of Mantap
"Mantap as a well-established, highly reputable and connected player in the market of PPE products, is the perfect fit for us to expand our market reach jointly. Their experienced and active team makes us look forward to continuing our journey together, which has already started at high speed."
- Kristoffer Ekman, CEO of NordShield®
Before the market entry of NordShield® Brilliant products, disinfectants have generally been based on alcohol as the active substance to eliminate germs. The effect of alcohol is short-lived, and after it has evaporated, typically in a matter of seconds, the treated surface is exposed to contamination again. NordShield® Brilliant products contain alcohol for the immediate kill effect; however, the long-lasting protection of the surface is derived from its disruptive technology based on the unique layer that does not evaporate but forms a durable physical, armor-like barrier on the treated surface. Thus, upon application, the unique barrier formulation of NordShield® Brilliant technology provides both an immediate kill and sustained protection of surfaces against microbes. The duration can vary based on the surface and the strain on it. The entire NordShield® Brilliant series has received the 3-star quality seal and rating "excellent" in dermatological tests conducted by renowned Dermatest GmbH in Germany.
About Mantap Perintis Sdn Bhd.
Mantap is an Asian market leader in personal protective equipment (PPE) and serves its clients with products ranging from disinfectants and nitrile gloves to face masks in Asia and across Europe. The company was founded in 2006, and operates globally with headquarters in Kuala Lumpur, Malaysia.
For more information, visit www.safeshield.com.my
Contact to Mantap:
Frankie Cheong, Company Director
Nordic BioTech Group, branded as NordShield®, is the world-leading innovative biotechnology company in developing new bio-based antimicrobial solutions. Founded in 2016 and headquartered in Espoo, Finland, NordShield® is disrupting the field of antimicrobial technology through a durable, wood-based alternative for antimicrobial surface protection utilized across applications and industries. NordShield®, as a commercial technology, was born after more than ten years of researching, developing, testing, verifying, certifying, and patenting. The result is a revolutionary technology with a unique combination of naturality, power and efficacy. This scalable technology enables the strongest protection with the highest innovativeness - a creation as unique and powerful as nature and one that leaves nothing but goodness behind.
For more information, visit www.nordshield.com
Contact to NordShield®:
Emmi Kavander, Chief Communications Officer
This document may contain statements related to Nordic Biotech Group Ltd's future business and financial performance and future events or developments that may constitute forward-looking statements. Nordic BioTech Group Oy does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated status of any such statements. Nordic Biotech Group neither intends nor assumes any obligation to update or revise these statements in light of developments that differ from those anticipated. Nordic BioTech Group Oy and its affiliates are not liable for any decision made or action taken in conjunction with the information and/or statement in this document or for any related damage.
This document contains statements that are only applicable within the European Union, and this document is intended only for distribution within the European Union. Nordic BioTech Group Oy does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of any such statements and is not liable for any such statements.